文献速递泌尿男性生殖肿瘤

个体化阿昔替尼方案用于经检查点抑制剂治疗后的转移性肾细胞癌患者:多中心单臂2期研究

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2019-08-16

该多中心单臂2期研究纳入40例经检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者,采用阿昔替尼起始5 mg每日两次、每14天按1 mg递增的个体化剂量方案。

要点

  • 最常见全级别不良事件为乏力(83%)和高血压(75%),3级高血压见于24例(60%)。
  • 该个体化滴定方案可行,未达到预设PFS阈值但显示稳健临床活性。

核心结论

  • 个体化阿昔替尼剂量滴定方案在经检查点抑制剂治疗的转移性肾细胞癌患者中未达到预设的无进展生存期阈值。
  • 该个体化滴定方案可行,并显示出稳健的临床活性,值得在此 setting 中考虑使用阿昔替尼。

研究设计与样本

  • 多中心、单臂、2期试验,评估个体化剂量算法给予阿昔替尼的活性。
  • 入组40例经组织学或细胞学确诊的局部复发或转移性透明细胞肾细胞癌患者,年龄≥18岁,Karnofsky体能状态≥70%,可测量病灶,且最近一次治疗为检查点抑制剂。
  • 阿昔替尼起始剂量为5 mg口服每日两次,每14天按1 mg递增(即5 mg每日两次至6 mg每日两次,最高10 mg每日两次),前提是无阿昔替尼相关≥2级黏膜炎、腹泻、手足综合征或乏力。
  • 主要终点为无进展生存期,按方案在所有至少接受一剂阿昔替尼的患者中分析。

主要发现

  • 2016年1月5日至2018年2月21日共入组40例患者并接受至少一剂研究治疗。
  • 最常见全级别不良事件为乏力(83%)和高血压(75%)。
  • 最常见3级不良事件为高血压(24例[60%]),1例(3%)4级不良事件为脂肪酶升高,无治疗相关死亡。
  • 可能与治疗相关的严重不良事件发生于8例(20%)患者,最常见为脱水(n=4)和腹泻(n=2)。

临床怎么用

  • 对于经检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者,可考虑使用个体化剂量滴定的阿昔替尼方案。
  • 采用起始5 mg每日两次、每14天按1 mg递增至最高10 mg每日两次的滴定策略,需监测黏膜炎、腹泻、手足综合征和乏力等不良反应。
  • 出现≥2级阿昔替尼相关黏膜炎、腹泻、手足综合征或乏力时,暂停给药3天后以原剂量恢复;若反复出现≥2级不良事件或发生3-4级不良事件,则需减量。

局限性

  • 单臂设计,无对照组,样本量较小(40例)。
  • 未达到预设的无进展生存期阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors, although no prospective data regarding their use in this setting exist. Axitinib is a VEGF-R inhibitor with clinical data supporting increased activity with dose titration. We aimed to investigate the activity of dose titrated axitinib in patients with metastatic renal cell carcinoma who were previously treated with checkpoint inhibitor. METHODS: We did a multicentre, phase 2 trial of axitinib given on an individualised dosing algorithm. Patients at least 18 years of age with histologically or cytologically confirmed locally recurrent or metastatic renal cell carcinoma with clear cell histology, a Karnofsky Performance Status of 70% or more, and measurable disease who received checkpoint inhibitor therapy as the most recent treatment were eligible. There was no limit on number of previous therapies received. Patients received oral axitinib at a starting dose of 5 mg twice daily with dose titration every 14 days in 1 mg increments (ie, 5 mg twice daily to 6 mg twice daily, up to 10 mg twice daily maximum dose) if there was no axitinib-related grade 2 or higher mucositis, diarrhoea, hand-foot syndrome, or fatigue. If one or more of these grade 2 adverse events occurred, axitinib was withheld for 3 days before the same dose was resumed. Dose reductions were made if recurrent grade 2 adverse events despite treatment breaks or grade 3-4 adverse events occurred. The primary outcome was progression-free survival. Analyses were done per protocol in all patients who received at least one dose of axitinib. Recruitment has been completed and the trial is ongoing. This trial is registered with ClincalTrials.gov, number NCT02579811. FINDINGS: Between Jan 5, 2016 and Feb 21, 2018, 40 patients were enrolled and received at least one dose of study treatment. With a median follow-up of 8·7 months (IQR 3·7-14·2), the median progression-free survival was 8·8 months (95% CI 5·7-16·6). Fatigue (83%) and hypertension (75%) were the most common all-grade adverse events. The most common grade 3 adverse event was hypertension (24 patients [60%]). There was one (3%) grade 4 adverse event (elevated lipase) and no treatment-related deaths occurred. Serious adverse events that were likely related to therapy occurred in eight (20%) patients; the most common were dehydration (n=4) and diarrhoea (n=2). INTERPRETATION: Individualised axitinib dosing in patients with metastatic renal cell inoma previously treated with checkpoint inhibitors did not meet the prespecified threshold for progression free survival, but these data show that this individualised titration scheme is feasible and has robust clinical activity. These prospective results warrant consideration of axitinib in this setting. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ornstein MC, Pal SK, Wood LS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019. PMID: 31427205. doi:10.1016/S1470-2045(19)30513-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。